Results 161 to 170 of about 114,702 (262)

Stem cell factor induces phosphatidylinositol 3'-kinase-dependent Lyn/Tec/Dok-1 complex formation in hematopoietic cells [PDF]

, 2000
Stem cell factor (SCF) has an important role in the proliferation, differentiation, survival, and migration of hematopoietic cells. SCF exerts its effects by binding to cKit, a receptor with intrinsic tyrosine kinase ...
Akker, E. (Emile) van den, Dijk, T.B. (Thamar) van, Lindern, M.M. (Marieke) von, Löwenberg, B. (Bob), Mano, H., Parren-Van Amelsvoort, M. (Martine)   +5 more
core   +1 more source

TNF Receptor-Associated Factor 4 (TRAF4) is a novel binding partner of glycoprotein Ib and glycoprotein VI in human platelets. [PDF]

, 2010
Background: Reactive oxygen species generation is one consequence of ligand engagement of platelet glycoprotein (GP) receptors GPIb-IX-V and GPVI, which bind VWF/collagen and initiate thrombosis at arterial shear, however the precise molecular mechanism ...
Andrews, R K, Arthur, J F, Berndt, Michael C, Coleman, Lorraine, Gardiner, E E, Kenny, Dermot, Shen, Y   +6 more
core  

Awareness and real-world practices in chronic lymphocytic leukemia: insights from a nationwide survey of Korean hematologists

Blood Research
Purpose The incidence of chronic lymphocytic leukemia (CLL) is rising in Korea; however, clinical management often diverges from international guidelines due to limited clinical experience, restricted access to diagnostics, and delayed reimbursement for ...
Seungah Cha, Seok Jin Kim, Kwai Han Yoo, EunHee Park, Ja Min Byun   +4 more
doaj   +1 more source

Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Monotherapy Compared with Combination Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis. [PDF]

Cancers (Basel), 2023
Nguyen TT, Nhu NT, Tran VK, Nguyen TTH, Lin CF.   +4 more
europepmc   +1 more source

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

Blood, 2012
S. Ponader, Shih-Shih Chen, J. Buggy, K. Balakrishnan, V. Gandhi, W. Wierda, M. Keating, S. O'brien, N. Chiorazzi, J. Burger   +9 more
semanticscholar   +1 more source

Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with chronic lymphocytic leukaemia. [PDF]

BMJ Open, 2023
Barber VS, Peckham N, Duley L, Francis A, Abhishek A, Moss P, Cook JA, Parry HM.   +7 more
europepmc   +1 more source

Treatment patterns in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post covalent Bruton tyrosine kinase inhibitor treatment: a Japanese claims database study. [PDF]

J Clin Exp Hematop, 2023
Maruyama D, Wang C, Tanizawa Y, Cai Z, Huang Y, Tajimi M, Kusumoto S.   +6 more
europepmc   +1 more source

A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia

Therapeutics and Clinical Risk Management, 2015
David L Tucker, Simon A Rule Department of Haematology, Plymouth Hospitals NHS Trust, Plymouth, UK Abstract: Although chemo-immunotherapy remains at the forefront of first-line treatment for mantle cell lymphoma (MCL) and chronic lymphocytic leukemia ...
Tucker DL, Rule SA
doaj  

Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies

European Journal of Haematology, 2018
B. Tillman, J. Pauff, G. Satyanarayana, M. Talbott, J. Warner   +4 more
semanticscholar   +1 more source

Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic. [PDF]

Neurol Neuroimmunol Neuroinflamm, 2021
Weber MS, Nicholas JA, Yeaman MR.
europepmc   +1 more source